Sarcoma, Soft Tissue
Conditions
Keywords
PD-1, doxorubicin, ifosfamide, first line treatment
Brief summary
This is a phase II trial to explore the feasibility of PD-1 immune check point inhibitor, sintilimab, in combination of stand of care chemotherapy in first-line treatment of selected soft tissue sarcoma.
Interventions
DRUGSintilimab
immune check point inhibitor, 200mg, iv, d1
DRUGDoxorubicin Hydrochloride
ADM, 60mg/m2, iv, d1
DRUGIfosfamide
IFO, 1.8 g/m2/d, d1-5
Sponsors
Zhejiang Cancer Hospital
Tongji Hospital
Xijing Hospital
Shanghai Zhongshan Hospital
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Men and women aged 18-75 years; * Provide written informed consent; * Local advanced or metastatic unresectable sarcoma; * Histologically confirmed undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma; * Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale; * Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; * Life span expectation over 3 months * Absolute neutrophil count (ANC) ≥1,500/mcL (within 7 days of treatment initiation) ； * Hemoglobin ≥9 g/dL (within 7 days of treatment initiation) ； * Platelets ≥ 90,000/mcL (within 7 days of treatment initiation) ； * Serum creatinine ≤ 1.5 X upper limit of normal (ULN) or creatinine clearance \[CrCl\]) ≥ 50 mL/min for subject with creatinine levels (within 7 days of treatment initiation) ； * Serum total bilirubin ≤ 1.5 X ULN (within 7 days of treatment initiation) ； * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 2.5 X ULN or =\< 5 X ULN for subjects with liver metastases (within 7 days of treatment initiation)；
Exclusion criteria
* Prior systemic therapy for advanced and metastatic disease, except adjuvant treatment（not received anthracycline）replase over 6 months; * Received any testing anti-cancer drugs within four weeks of treatment initiation; * Prior immune related therapy including but not limited to PD-1, PD-L1, CD137, CTLA4, T cell stimulation, check point inhibitor etc; * Symptomatic, untreated, or uncontrolled brain metastases present * clinical meaningful active bleeding; * Other malignant cancer history rather than soft tissue sarcoma within five year prior to treatment initiation; * Have active infections requiring therapy; * Have active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients that require inhaled steroids or local steroid injections would not be excluded from the study. Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study. * Pregnant or breast-feeding； * Any serious or unstable medical condition or mental illness； * Serious systemic diseases such as heart disease, history of (non-infectious) pneumonitis; * Active HBV （\>10000 copy/ml） and HCV （RNA\> 1000copy/ml） infection； * Positive human immunodeficiency virus (HIV）or any acquired immunodeficiency syndrome, organ implantation;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate, ORR | up to two years | the best response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival, PFS | up to three years | from first dose treatment to disease progression |
| adverse events, AE | up to three years | treatment related adverse events, TRAEs |
| overall survival, OS | up to three years | overall survival |
Other
| Measure | Time frame | Description |
|---|---|---|
| PD-L1 expression | up to two years | PD-L1 expression will be detected by Immunohistologic chemistry, IHC or PCR method |
| tumor infiltrating lymphocytes measurement | up to two years | tumor infiltrating lymphocytes will be measured by flowcytometry using tissue and/or peripheral blood sample； |
Countries
China
Contacts
Primary ContactXin Liu, MD
Outcome results
None listed